

ARRHYTHMOGENIC CARDIOMYOPATHY

A research project coordinated by the University of Padua has been funded with 4 million euros.

The research project, named **IMPACT** - Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment - will run for 36 months and has been funded with 4 million euros by the European Innovation Council for cardiogenomics. The mission of the European Innovation Council (EIC), established by the European Commission in 2021, is to identify and to develop innovative technologies for research.

The international team, led by Professor Alessandra Rampazzo of the Department of Biology at the University of Padua and composed of researchers from Universiteit Maastricht (Dr. Martina Calore), Universitair Medisch Centrum Utrecht (Dr. Anneline te Riele), **Lutech Group (Dr. Barbara Alicino)**, Italbiotec Consortium (Dr. Melissa Balzarotti), Ksilink (Dr. Peter Sommer), and Italfarmaco (Dr. Christian Steinkuhler), will study **the development of new therapies for arrhythmogenic cardiomyopathy (ACM), a genetic disease that affects the heart and represents one of the main causes of ventricular arrhythmias and sudden cardiac death**. With an incidence of 1 in 5000, it can be considered a highly relevant cardiovascular disease.

Arrhythmogenic cardiomyopathy is a degenerative heart condition often implicated in the sudden death of athletes and adolescents. The histopathological hallmark is fibroadipose replacement of the myocardium, which impairs the functioning of the cardiac muscle, leading to the onset of ventricular arrhythmias. Currently, there is no therapy available to prevent or at least slow down the progressive tissue changes that could be ultimately fatal.

Mutations in numerous disease genes have been identified as contributors to this condition. However, many of the genetic alterations found in the DNA of affected patients have uncertain significance and are not yet directly linked to the disease, providing limited utility for both geneticists and physicians.

«Thanks to the funding obtained from Horizon Europe, our research project aims to open up new therapeutic perspectives based on the results obtained from various disease models. This is an innovative and multidisciplinary project, whose success is strongly supported by the diverse but complementary expertise of partners from academic institutions and leading companies in the fields of computer science, biotechnology, and pharmaceuticals," says **Professor Alessandra Rampazzo of the Department of Biology at the University of Padua and scientific coordinator of the international team**. "Such collaboration will allow us to achieve our ambitious goals. The overall objective of the project funded by the European Community is to integrate and analyze clinical and molecular data from the ACM patient registry using artificial intelligence, along with data from structural and functional analyses of cellular models such as three-dimensional cardiac microtissues and



in vivo models. These results will enable us to gain a better understanding of the role and impact of genetic alterations on the clinical progression of arrhythmogenic cardiomyopathy. Additionally," **Alessandra Rampazzo concludes**, "the project includes screening and subsequent evaluation of the therapeutic potential of several compounds and innovative molecules, both in cellular and animal models. »

«We are proud to be part of this ambitious research project about arrhythmogenic cardiomyopathy research project," says **Franco Prampolini, Head of Advanced Industry Solutions at Lutech Group**. At Lutech, we believe that the key to making significant progress in understanding and treating this serious cardiovascular disease is collaboration between partners with complementary skills. We are grateful to Horizon Europe for supporting this initiative, which will enable us to provide digital expertise and solutions for analyzing and understanding clinical data also through the use of artificial intelligence.»

The discovery of new therapeutic targets and an understanding of the underlying molecular mechanisms could not only lead to new therapies for ACM but could also pave the way for better clinical management of the disease and an improvement in the quality of life for patients.

The meeting of all participants, which will officially launch the project, will be held in Padua on October 26th and 27th.

Contatti per la stampa – Gruppo Lutech

Alice Di Prisco

alice.diprisco@lutech.it

Sara Antonelli

s.antonelli@lutech.it

Contatti per la stampa – Comin & Partners

Francesca Martella

3393148115

francesca.martella@cominandpartners.com

Lutech Group Profile

Il Gruppo Lutech progetta, realizza e gestisce soluzioni per la trasformazione digitale, l'innovazione e la crescita di aziende e Istituzioni, grazie ad una conoscenza approfondita dei processi specifici delle diverse industry.

Tra i primi tre player in Italia nei servizi di Digital Evolution, con 4.700 professionisti e ricavi per circa 800 milioni di euro, il Gruppo Lutech guida il cambiamento attraverso una percorso end-to-end in cui business consulting, execution e governance massimizzano i risultati delle aziende, grazie a sei anime tecnologiche concepite per un'offerta completa ed integrata: Lutech**Consulting**, Lutech**Solutions**, Lutech**Digital**, Lutech**Cybersecurity**, Lutech**Services** e Lutech**Cloud**.

Per ulteriori informazioni, visita il sito web www.lutech.group

WWW.LUTECH.GROUP

Lutech SpA · Società unipersonale.

Sede legale Via Dante 14 - 20121 Milano, Italia · lutechspa@legalmail.it · C.S.: € 3.210.000,00 i.v. · C.F. / P.IVA: 02824320176 · REA-MI: 1666842

HQ Via Massimo Gorki 30/32C - 20092 Cinisello Balsamo (MI), Italia · 02 2542 7011 · Fax 02 2542 7090

